What Microbio Co. does

Microbio Co., Ltd. (TPEx: 4128) is a Taiwanese biotechnology company founded in 2000 and headquartered in Taipei, operating across drug development, postbiotic ingredients, cosmeceuticals, organic retail, and biotech venture investments. Its core technology is the proprietary Symbiota™ precision anaerobic symbiotic co-fermentation platform, which uses multiple gut probiotic strains to produce metabolite-rich postbiotic fermentates that are then formulated across nutraceutical, cosmetic, and pharmaceutical applications.

The product portfolio is built on this single underlying platform. Pharmaceutical assets include MS-20 (MICRSOY oral solution) — Taiwan's first approved oral new drug derived from microbiome technology, shown to enhance PD-1 antibody immunotherapy in late-stage non-small cell lung cancer — plus Herbiron and the SNS851 siRNA weight-loss drug in Phase 1 (Australia, February 2026). Nutraceutical and functional-food ingredients under the Symbiota™ brand include SKUs 020 (gut and immune health), 901 (glucose metabolism and GLP-1 support), 217 (liver health), and 191 (healthy puberty timing). Cosmetic actives comprise Symbiota™ 701 (postbiotic skincare, with published clinical outcomes in atopic dermatitis) and NEXOSOME™ (anti-aging). MB107 cream is a regulated medical device (ISO 13485 certified, March 2025).

Microbio monetizes through a hybrid of one-time drug license revenue (MS-20, Herbiron, Sandipan via Huarun Shuanghe for China), B2B ingredient sales to cosmetic and nutraceutical brands, recurring retail sales through the wholly-owned Cotton Field Organic subsidiary (80 stores in Taiwan under an OMO strategy), and biotech VC investments. Distribution channels span domestic retail, hospital and clinic partnerships for MS-20 education, international B2B sales, and licensing agreements in China. The group structure includes publicly listed affiliates Oneness Biotech (4743) and Diamond Investment (6901), plus operating subsidiaries Microbio (Shanghai) and Cotton Field Organic. Regulatory milestones in 2024–2026 — U.S. GRAS, EU Not Novel food, ISO 13485, Australian HREC/TGA — have opened the U.S., EU, and Australia markets alongside Taiwan and China.

Name

Microbio Co.

Legal name

中天生物科技股份有限公司

Website

https://twmicrobio.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Microbio Co., Ltd. (TPEx: 4128) is a Taiwanese biotech that develops new drugs, postbiotic nutraceutical and cosmetic ingredients, and medical devices from its proprietary Symbiota™ anaerobic co-fermentation platform, serving cancer patients, metabolic-disorder patients, health-conscious consumers, and B2B cosmetic brands across Taiwan, the EU, U.S., China, and Australia.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals and Postbiotics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Microbiome-Derived Metabolite Therapeutics (postbiotics) (HLAAAFAB)

Keywords

• Postbiotic ingredients
• Biopharmaceutical development
• Gut microbiome therapeutics
• Symbiotic fermentation technology
• Organic health supplements

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. New Drug Development and Sales: Microbio develops and commercializes novel drugs including MS-20 (approved oral new drug for cancer immunotherapy enhancement) and Herbiron. The company holds drug license permits from Taiwan's Ministry of Health and Welfare for these products.
2. Functional Health Supplements: Products developed using the Symbiota technology platform marketed through organic retail channels, including Cotton Field Organic stores. Product lines include Symbiota™ 020 (Gut & Immune Health), Symbiota™ 901 (Glucose Metabolism & GLP-1 Support), Symbiota™ 217 (Liver Health), and Symbiota™ 191 (Healthy Puberty Timing).
3. Cosmetic Ingredients: Sale of proprietary postbiotic ingredients (Symbiota™ 701, NEXOSOME™) to cosmetic and skincare brands for incorporation into formulations.
4. Organic Products (Cotton Field): Cotton Field Organic subsidiary operates 80 stores as of 2024, implementing an omnichannel strategy (OMO - Online Merge Offline) to expand store network and promote organic and healthy brand value.
5. Biotech Venture Capital Investments: The group is actively engaged in biotech venture capital investments, collaborating with domestic and international research institutions and pharmaceutical companies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Microbio Co. is a Taiwanese biotechnology company that develops and commercializes pharmaceutical drugs, postbiotic ingredients, and health supplements based on its proprietary Symbiota™ precision symbiotic fermentation platform. Its portfolio includes approved oral new drugs (MS-20/MICRSOY), cosmetic ingredients, nutraceutical ingredients, siRNA drugs in clinical trials, and an organic retail chain (Cotton Field Organic).

Product overview

Microbio Co. is a biotechnology company offering a diversified portfolio centered on its proprietary Symbiota™ postbiotic technology platform. The core technology uses multiple gut probiotic strains with anaerobic symbiotic co-fermentation to produce metabolite-rich fermentates. The product portfolio includes: (1) nutraceutical ingredients under the Symbiota™ brand (020, 901, 217, 191) for gut health, glucose metabolism, liver health, and puberty support; (2) cosmetic ingredients including Symbiota™ 701 and NEXOSOME™ for skin microbiome and anti-aging applications; (3) new drug development including MS-20 (Taiwan's first approved oral postbiotic drug for cancer immunotherapy support), Herbiron, and SNS851 (siRNA metabolic disorder drug in Phase 1); (4) health supplements including Tien Chun Bao and Li Shizhen Six Flavor Compound; and (5) organic retail operations through subsidiary Cotton Field Organic. The company also provides turnkey solutions and medical device development services.

Differentiator

Problem solved

Functional benefit

Brands

• Symbiota™: Gut microbiome platform developed through anaerobic symbiotic co-fermentation technology using multiple probiotic strains; includes various functional health formulations and the approved oral new drug MS-20
• MS-20
• Herbiron
• Cotton Field Organic
• Symbiota™ 701
• NEXOSOME™
• Tien Chun Bao
• Li Shizhen Six Flavor Compound

Products and services

• Symbiota™ Platform Proprietary precision-engineered postbiotic technology platform developed through anaerobic symbiotic co-fermentation using multiple probiotic strains to produce metabolite-rich fermentates for pharmaceutical, nutraceutical and cosmetic applications.
• Symbiota™ 020

Quantifiable outcome

• EASI scores reduced by approximately 48% with Symbiota™ 701 in atopic dermatitis study
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Oneness Biotech Co., Ltd. (合一生技)coreStrategic or Co-development Partner · 24 February 2026Joint development partnership for SNS851 siRNA drug for metabolic disorders. SNS851 is a novel weight-loss drug with new mechanism of action jointly developed by Oneness Biotech and Microbio (Shanghai). The Phase 1 clinical trial was approved by Australian HREC and acknowledged by TGA in February 2026.
• Cotton Field Organic (棉花田生機園地)coreOthersSubsidiary focused on organic and healthy brand value, implementing omnichannel strategy (OMO) with 80 stores as of 2024. Products developed using Symbiota technology are marketed through Cotton Field Organic retail channels.
• Microbio (Shanghai) Co., Ltd. (中天(上海)生物科技有限公司)coreOthersSubsidiary of Microbio Co., Ltd. jointly developing SNS851 with Oneness Biotech. Also developing other products including the '速必一' (Sandipan) medical device.
• Huarun Shuanghe Pharmaceutical Co., Ltd. (華潤雙鶴藥業)coreStrategic or Co-development PartnerPartnership for commercialization of '速必一' (Sandipan) 香雷糖足膏 in mainland China. Exclusive commercialization licensing agreement signed for the mainland China market.
• Taiwan Cancer Nutrition and Immunity AssociationminorOthersSocial welfare partnership for promoting cancer health education and providing support to cancer patients.
• BoYo Social Welfare FoundationminorOthersSocial welfare partnership providing educational resources for children in rural areas.
• Taishin International BankminorOthersPartnership with Cotton Field Organic to promote organic agriculture and donate healthy Lunar New Year dishes to childcare institutions.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

Emerging players

• Assembly Biosciences: US clinical-stage microbiome therapeutics company developing engineered microbial consortia. Comparable as a listed pure-play in microbiome drug development, though focused on different indications.
• Second Genome (now BioElectron): US-based microbiome drug discovery company that pivoted into enzyme therapeutics. Comparable as a peer in microbiome-based drug R&D with platform technology and clinical pipeline ambitions.
• Immuron: Australian microbiome therapeutics company developing oral polyclonal antibodies for gut-related conditions. Comparable to MS-20 as an oral microbiome-derived therapeutic with clinical-stage immuno-oncology adjacency (travel-related diarrhea, gut inflammation).

Broad incumbents

• Novonesis (formerly Chr. Hansen): Global bioscience giant combining legacy Chr. Hansen cultures/probiotics with Novozymes enzyme business. Comparable as a broad incumbent in microbial fermentation and postbiotic/probiotic ingredient supply at industrial scale.
• Kerry Group (incl. Ganeden): Irish taste and nutrition multinational that acquired Ganeden, a leading probiotic/postbiotic ingredient company. Directly comparable to Microbio's Symbiota 020/901/217 ingredient lines in B2B functional food and supplement channels.
• Lallemand Health Solutions: Canadian-based probiotic/postbiotic ingredient supplier serving global nutraceutical brands. Overlaps with Microbio's Symbiota ingredient portfolio and B2B health-supply customers.

Direct peers

• Oneness Biotech (合一生技): Taiwanese biotech listed on TPEx (4743) and a strategic Microbio Group affiliate. Co-develops SNS851 siRNA with Microbio (Shanghai) and shares corporate governance ecosystem, making it the most direct comparable in pipeline and listing structure.
• BioGaia: Swedish probiotics and postbiotics company selling probiotic strains, infant nutrition, and gut-health supplements globally. Most directly comparable to Microbio's Symbiota nutraceutical ingredient business and B2B licensing model.

Regional players

• AB Biotics (Hyphens Pharma): Singapore-listed probiotics company with proprietary probiotic strains distributed primarily across Asia. Comparable in probiotic strain R&D and Asian nutraceutical market positioning.

Others

• Diamond Biofund: Part of the Microbio Group ecosystem, providing biotech venture capital exposure. Adjacent rather than competing — relevant for understanding the broader group's strategic asset allocation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/microbiocoltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microbio Co.